Provide proposal package to Congress outlining the recommendations for reauthorization of the A/GDUFA programs to continue to collect fees for certain animal drug applications, and for the establishments, products and sponsors associated with these and previously approved animal drug applications, in support of the review of pioneer and generic animal drugs. (1) ON TRACK ON TRACK main 1. Gather feedback on suggestions regarding reauthorization including specific suggestions for changes to the A/GDUFA goals, hold a public meeting and open a docket to gather written comments 11/7/2011 Completed 11/7/2011 main 2. Analyze written comments submitted to the docket to inform stakeholder and industry discussions 12/30/2011 Completed 12/7/2011 main 3. Conduct periodic consultations with representatives of veterinary, patient, and consumer advocacy groups to continue discussions of their views on reauthorization and their suggestions for changes 5/30/2012 <i>(7/31/2012)</i> Completed 7/19/2012 main 4. Conduct negotiations and reach agreement with the regulated industry on user fee program reauthorizations sub a. ADUFA Program 7/24/2012 Completed 7/24/2012 sub b. AGDUFA Program 6/30/2012 Completed 4/19/2012 main 5. Submit draft package of proposal recommendations for reauthorizations for administration review and clearance 8/1/2012 <i>(10/15/2012)</i> Completed 9/13/2012 main 6. Publish draft proposed recommendations in Federal Register and provide 30-day comment period 9/15/2012 <i>(10/19/2012)</i> Completed 12/5/2012 main 7. Hold a public meeting to gather feedback on the proposed recommendations for reauthorization 11/1/2012 <i>(11/20/2012)</i> Completed 12/18/2012 main 8. Revise recommendations as necessary per public input 12/15/2012 <i>(12/31/2012)</i> <i>(1/14/2013)</i> Completed 1/9/2013 main 9. Transmit final package of prepared recommendations for reauthorization to Congress by January 15, 2013 1/15/2013 Not Yet Started (1) The dates in italics under the milestone due dates are modified due dates which had to be updated due to real-time delays. The milestone status reflects the modified dates. http://www.fda.gov/AboutFDA/Transparency/track/ucm203425.htm FDA-TRACK CVM Dashboard ਍††਍਍਍਍਍਍਍